Standout Papers

Pembrolizumab as Second-L... 2014 2026 2018 2022 2017 2017 2014 2019 2021 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →
  2. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →
  3. EAU Guidelines on Penile Cancer: 2014 Update
    2014 412 citations Oliver W. Hakenberg, Éva Compérat et al. European Urology profile →
  4. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
    2019 294 citations Yves Fradet, Joaquim Bellmunt et al. Annals of Oncology profile →
  5. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2021 294 citations Tom Powles, Joaquim Bellmunt et al. Annals of Oncology profile →
  6. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
    2023 206 citations Ibrahim Jubber, Sean Ong et al. European Urology profile →
  7. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
    2021 168 citations Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology profile →
  8. Penile cancer
    2021 127 citations Anita Thomas, Andrea Necchi et al. Nature Reviews Disease Primers profile →
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
    2024 63 citations Thomas Powles, Joaquim Bellmunt et al. Annals of Oncology profile →

Immediate Impact

3 by Nobel laureates 42 from Science/Nature 85 hit
Sub-graph 1 of 21

Citing Papers

The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion
2023 HitNature
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
2023 HitNature
2 intermediate papers

Works of Andrea Necchi being referenced

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019 Hit
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Hit
and 1 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Andrea Necchi 8.7k 5.7k 2.7k 2.0k 1.2k 580 12.1k
Dean F. Bajorin 15.5k 1.8× 8.0k 1.4× 4.9k 1.9× 4.2k 2.1× 1.7k 1.4× 491 21.3k
Thomas Powles 5.1k 0.6× 5.9k 1.0× 2.8k 1.1× 1.9k 0.9× 1.8k 1.6× 336 10.4k
Christine Théodore 3.9k 0.4× 3.5k 0.6× 6.0k 2.2× 2.1k 1.0× 388 0.3× 164 10.5k
Siamak Daneshmand 8.6k 1.0× 1.7k 0.3× 2.5k 0.9× 1.7k 0.8× 175 0.2× 466 10.8k
Paul Perrotte 5.0k 0.6× 3.2k 0.6× 7.7k 2.9× 3.5k 1.7× 418 0.4× 311 12.5k
Esther Oliva 2.6k 0.3× 1.9k 0.3× 3.7k 1.4× 3.2k 1.6× 515 0.4× 294 12.9k
Yohann Loriot 4.3k 0.5× 6.2k 1.1× 4.5k 1.7× 2.4k 1.2× 1.5k 1.3× 455 11.7k
Jonathan E. Rosenberg 6.8k 0.8× 5.5k 1.0× 4.1k 1.5× 4.2k 2.1× 1.1k 0.9× 403 13.3k
Jae‐Lyun Lee 4.7k 0.5× 6.1k 1.1× 5.1k 1.9× 2.7k 1.3× 1.0k 0.9× 391 11.3k
Thomas M. Ulbright 8.6k 1.0× 2.6k 0.5× 6.7k 2.5× 4.8k 2.4× 249 0.2× 303 15.2k

All Works

Loading papers...

Rankless by CCL
2026